You are here: Industry Insights > AVEO

News List

AVEO Oncology warns of "regulatory action" by EMA if overall survival results for Fotivda come up short pharmatimes
April 04, 2019
AVEO Oncology disclosed in a filing with the US Securities and Exchange Commission that the European Medicines Agency will consider "regulatory action" if an interim overall survival (OS) analysis from the TIVO-3 trial confirms a negative trend for Fotivd
AVEO Oncology Announces Clinical Collaboration with AstraZeneca americanpharmaceuticalreview
December 24, 2018
AVEO Oncology has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's Imfinzi (durvalumab).....
AZ begins liver cancer immunotherapy tie-up with AVEO pharmaphorum
December 14, 2018
AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.
AstraZeneca, AVEO Oncology form lung cancer collaboration pharmatimes
December 13, 2018
AVEO Oncology has announced the start of an immuno-oncology focused clinical collaboration with drug giant AstraZeneca (AZ).
Novartis dumps Aveo drug as relationship sours fiercebiotech
July 09, 2018
Novartis has walked away from Aveo Pharmaceuticals’ AV-380 three years after paying $15 million (€13 million) upfront for the asset.
Aveo's phoenix drug tivozanib rises up in Europe fiercebiotech
August 29, 2017
EUSA Pharma says it will make the drug available to kidney cancer patients across Europe "as quickly as possible."
AVEO Announces Clinical and Regulatory Updates for Tivozanib americanpharmaceuticalreview
February 13, 2017
AVEO Oncology has announced clinical and regulatory updates for its lead drug candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).